How safe is CBD?

Many people are concerned with the safety of CBD use, and worry about the current lack of FDA approval for most CBD products currently on the market (the drug Epidiolex conatins CBD and was approved by the FDA for treatment of severe epileptic seizures). As we've mentioned in previous posts, the World Health Organization has... Continue Reading →

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Abstract Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses... Continue Reading →

Cannabinoids and schizophrenia: therapeutic prospects.

Abstract Approximately one third of patients diagnosed with schizophrenia do not achieve adequate symptom control with standard antipsychotic drugs (APs). Some of these may prove responsive to clozapine, but non-response to APs remains an important clinical problem and cause of increased health care costs. In a significant proportion of patients, schizophrenia is associated with natural... Continue Reading →

Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.

Abstract Cannabis use and the development of schizophrenic psychoses share a variety of similarities. Both start during late adolescence; go along with neuropsychological deficits, reduced activity, motivation deficits, and hallucinations suggesting impairment of similar brain structures. In cannabis heavy users diminished regional gray and white matter volume was reported. Similar alterations were observed in the... Continue Reading →

Cannabidiol as a Potential Treatment for Pyschosis

Abstract Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the... Continue Reading →

Up ↑